Final Analysis of Phase 2 GRIFFIN Study Presented for DARZAL

Data featured in plenary session at the 19th International Myeloma Society Annual Meeting LOS ANGELES, Aug. 27, 2022 /PRNewswire/ -- The Janssen Pharm

Related Keywords

Virginia , United States , Chicago , Illinois , American , Bortezomib Melphalan , Douglasw Sborov , Velcade Melphalan , Velcade Bortezomib Melphalan , Imran Khan , Christie Corbett , Amgen , Myeloma Program , Janssen Biotech Inc , University Of Utah , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , National Library Of Medicine , European Myeloma Network , American Cancer Society , None Of The Janssen Pharmaceutical Companies , Hematology At Janssen Scientific Affairs , Huntsman Cancer Institute , International Myeloma Society , Exchange Commission , Companies Of Johnson , International Myeloma Society Annual Meeting , Johnson , Multiple Myeloma Program , Medical Affairs , Janssen Scientific Affairs , Janssen Biotech , Interference With Serological , With Determination , Pharmaceutical Companies , Infectious Diseases , Janssen Research , Private Securities Litigation Reform Act , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Plus Lenalidomide , Final Analysis , Prescribing Information , Annual Meeting , American Society , Clinical Oncology , Study Comparing Daratumumab , Dexamethasone With Lenalidomide , Refractory Multiple , National Library , Participants With Relapsed , Evaluate Daratumumab , Velcade Melphalan Prednisone , Comparing Daratumumab , Participants With Previously Untreated Multiple , Combination With , High Dose Therapy , Asia Pacific Region , Compare Progression Free Survival Btw , Patients With Relapsed , Statistics About Multiple Myeloma , Accessed August ,